Wexler Wallace Files Case Against Wyeth for Effexor XR
Wexler Wallace LLP, with co-counsel Branstetter Stranch & Jennings, PLLC, and Trujillo Rodriguez and Richards, LLC, filed a case against Wyeth, Inc. on behalf of Indirect Purchasers of the antidepressant Effexor XR. The plaintiffs allege that Wyeth fraudulently obtained a number of method of use patents for Effexor XR and engaged in sham litigation against 16 potential generic competitors in an effort to protect the Effexor XR monopoly.
As part of the scheme, plaintiffs also allege that Wyeth entered into an anticompetitive settlement with the first generic ANDA filer, Teva. As a result of these actions, generic Effexor XR competition was delayed for more than 2 years. For a copy of the consolidated complaint, click here.
On December 14, 2011, Kenneth A. Wexler was appointed interim class counsel for the End-Payor class, along with Jeffrey L. Kodroff of Spector Roseman Kodroff & Willis P.C., James E. Cecchi of Carella Byrene Cecchi Olstein Brody & Agnello, P.C., Michael M. Buchman of Pomerantz Haudek Grossman & Gross LLP, Richard J. Burke of Freed & Weiss LLC, and James R. Dugan, II, of The Dugan Law Firm. Lisa J. Rodriguez of Trujillo Rodriguez & Richards, LLC, was appointed Liaison Counsel for the putative class. For a copy of the Court’s Order appointing Wexler Wallace LLP as interim class counsel, click here.